WOW! I know this morning is a bloodbath for the markets. 🩸
I haven’t seen anything like this since after the Covid news came out a few years ago.
As a trader who’s been doing this for over 20 years, let me reassure you of something – don’t panic!
I am not going to tell you this is the time to buy or sell anything, but I think it is important for you to take a step back and make sure you are not overreacting and trading emotionally.
Think about this… Every single person right now wants to sell everything they have and go to cash.
Do you think that is a good thing to do when the herd is all headed in the same direction?
Anyways, I just don’t want you to ever trade without having a good plan in place and make sure you stick to it.
I can tell you that I won’t be trading QQQ as usual or any big tech stocks today.
This is not the environment I want to trade in, so I don’t have to.
I want to go after smaller stocks that are less impacted by overall markets.
Just like the mobile alert, I sent you on Friday that jumped over 25% during the day.
Today, there is a recent “reverse split” stock I think you should pay attention to.
Go to your platform and pull up Alzamend Neuro (ALZN) right now.
I really like reverse split stocks in this market, let me explain why.
Pretend there are 10 million shares of stock issued for a company.
If this company does a “10 for 1” reverse split, that would mean there are now only 1 million shares issued.
Effectively, the amount of shares available has decreased by 90% in this case.
It appears that traders, in general, love this because it also increases the volatility. That means the price can move a lot easier (either up or down.)
If you’ve been watching smaller stocks this year, a lot of them that have “blown up” over 100% or more in a day have been recent reverse split stocks, for exactly this reason.
Today is a great example of this.
If you look at the pre-market trading, you’ll see that ALZN is already on the move…
As I said, this is not a stock that is going to be heavily influenced by what is happening with the global markets today.
A few minutes ago, ALZN just announced a significant development with their Phase 2 clinical trial for Alzheimer’s.
This is exactly the type of news that can make the stock stand out today.
As you can see, it is already one of the top-gaining stocks this morning on that news.
ALZN is a reverse split stock that is not on the radar of many traders yet. I imagine that is going to change very quickly, though.
Today is the day you need to get ALZN on your radar!
As you are doing your homework on it, here are some points I found interesting…
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer’s, bipolar disorder (BD), Major depressive disorder (MDD), and PTSD.
As I’m sure you know, these diseases are huge problems, with more than 43 million Americans suffering from them.
The Atlanta-based company has two main candidates, AL001 and ALZN002.
Its lead candidate, AL001, is a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, which the company believes is a potential replacement to current marketed lithium treatments (lithium carbonate and lithium citrate) and provide significant benefit to the 43 million American suffering with Alzheimer’s disease, BD, MDD and PTSD.
Preclinical data “showed prevention of cognitive deficits, depression and irritability in . . . mice, and is superior in improving associative learning, memory, and irritability, compared with lithium carbonate treatments.”
You’ve probably heard about lithium as a treatment for various psychiatric disorders, especially bipolar disorder, for which it is the first mood stabilizer and first-line treatment and considered the gold standard treatment…
Well, AL001 is designed to provide the benefits of traditional lithium while reducing its harmful side effects. It distributes lithium more safely in the brain, avoiding high levels in other organs and making it safer and more convenient for patients.
Phase I and Phase IIa trials confirmed that AL001, at a lithium content equivalent to150 mg lithium carbonate is bioequivalent to 300 mg of the currently marketed lithium carbonate capsule.
ALZN is hopeful that its formulation could supplant marketed lithium therapies, and — critically — not require Therapeutic Drug Monitoring (TDM) the way those therapies do.
ALZN’s other key candidate is ALZN002 — a patented method that uses “a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.”
The idea is to take white blood cells from a patient’s body and engineer them to attack Alzheimer’s-related amyloid-beta proteins. This is expected to provide a safe and effective treatment for Alzheimer’s sufferers that requires considerably less frequent treatment visits compared to passive immunity approaches of the currently marketed immunotherapies.
As the company explains:
- ALZN002 is based on the theory that Alzheimer’s symptoms may be caused in large part by plaque deposits that can cluster in the brain composed of protein fragments called beta-amyloids that build up between nerve cells.
- One hypothesis is that a special type of immune cell, natural beta-amyloid antibodies, may play a role in preventing plaque build-up in people without Alzheimer’s. As people age, their immune systems may degrade, and some people may be unable to produce natural beta-amyloid antibodies, the absence of which leads to the plaque build-up causing Alzheimer’s.
- ALZN002 is intended to elicit an immune response to produce anti-amyloid antibodies, which can then neutralize circulated beta-amyloids and prevent additional plaque build-up.
- Compared to passive immunization treatment approaches that use foreign blood products (such as monoclonal antibodies), active immunization with ALZN002 is anticipated to offer a more robust and long-lasting effect on the clearance of amyloid.
For more information on Alzamend Neuro and the company’s groundbreaking work, visit https://www.alzamend.com.
Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.
Bottom line: It is a very rough day for the markets, I would encourage you to look at winning opportunities out there. ALZN is one of the few winning stocks this morning that is actually moving up as I type this!
Make sure you are watching ALZN as early as possible today. It could be a big one!
To Your Success,
Jeff Bishop
P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now.
*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”
Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Sica Media for advertising Alzamend Neuro, Inc for a one day marketing program on August 5, 2024. This amount was paid by someone else not connected to Alzamend Neuro, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.
Now, diving right into Alzamend Neuro, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.
So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.